1. Home
  2. SLGB vs MRKR Comparison

SLGB vs MRKR Comparison

Compare SLGB & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smart Logistics Global Limited Ordinary Shares

SLGB

Smart Logistics Global Limited Ordinary Shares

N/A

Current Price

$0.30

Market Cap

23.3M

Sector

Industrials

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

N/A

Current Price

$0.98

Market Cap

19.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SLGB
MRKR
Founded
2017
1999
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Integrated Freight & Logistics
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.3M
19.5M
IPO Year
2023
2010

Fundamental Metrics

Financial Performance
Metric
SLGB
MRKR
Price
$0.30
$0.98
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.87
AVG Volume (30 Days)
★ 249.5K
168.4K
Earning Date
12-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.61
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$19.61
Revenue Next Year
N/A
$375.85
P/E Ratio
$29.95
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.18
$0.84
52 Week High
$4.22
$2.46

Technical Indicators

Market Signals
Indicator
SLGB
MRKR
Relative Strength Index (RSI) 57.32 45.81
Support Level $0.27 $0.88
Resistance Level $0.32 $1.32
Average True Range (ATR) 0.03 0.12
MACD 0.01 0.00
Stochastic Oscillator 50.19 31.33

Price Performance

Historical Comparison
SLGB
MRKR

About SLGB Smart Logistics Global Limited Ordinary Shares

Smart Logistics Global Ltd is a contract logistics solution provider in the PRC. The company focuses on industrial raw materials line-haul transportation business. The group focuses on developing a road-transport smart logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: